Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply

Detalles Bibliográficos
Autores principales: Maselkar, Sheetal, Kiazand, Alexandre, Templeton, Alison, Montgomery, Hugh, Esser, Mark T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779778/
https://www.ncbi.nlm.nih.gov/pubmed/36521509
http://dx.doi.org/10.1016/S2213-2600(22)00450-7
_version_ 1784856693103919104
author Maselkar, Sheetal
Kiazand, Alexandre
Templeton, Alison
Montgomery, Hugh
Esser, Mark T
author_facet Maselkar, Sheetal
Kiazand, Alexandre
Templeton, Alison
Montgomery, Hugh
Esser, Mark T
author_sort Maselkar, Sheetal
collection PubMed
description
format Online
Article
Text
id pubmed-9779778
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-97797782022-12-23 Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply Maselkar, Sheetal Kiazand, Alexandre Templeton, Alison Montgomery, Hugh Esser, Mark T Lancet Respir Med Correspondence Published by Elsevier Ltd. 2023-01 2022-12-12 /pmc/articles/PMC9779778/ /pubmed/36521509 http://dx.doi.org/10.1016/S2213-2600(22)00450-7 Text en © 2022 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Maselkar, Sheetal
Kiazand, Alexandre
Templeton, Alison
Montgomery, Hugh
Esser, Mark T
Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
title Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
title_full Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
title_fullStr Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
title_full_unstemmed Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
title_short Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
title_sort cardiac and vascular serious adverse events following tixagevimab–cilgavimab – author's reply
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779778/
https://www.ncbi.nlm.nih.gov/pubmed/36521509
http://dx.doi.org/10.1016/S2213-2600(22)00450-7
work_keys_str_mv AT maselkarsheetal cardiacandvascularseriousadverseeventsfollowingtixagevimabcilgavimabauthorsreply
AT kiazandalexandre cardiacandvascularseriousadverseeventsfollowingtixagevimabcilgavimabauthorsreply
AT templetonalison cardiacandvascularseriousadverseeventsfollowingtixagevimabcilgavimabauthorsreply
AT montgomeryhugh cardiacandvascularseriousadverseeventsfollowingtixagevimabcilgavimabauthorsreply
AT essermarkt cardiacandvascularseriousadverseeventsfollowingtixagevimabcilgavimabauthorsreply

Ejemplares similares